Ascletis Pharma Inc. (01672) disclosed its Monthly Return on Movements in Securities for the period ended 28 February 2026. The total authorized share capital remained at 7.00 billion ordinary shares, with each share carrying a par value of USD 0.0001, equating to a total authorized share capital of USD 700,000.

At the close of the preceding month, 991.87 million issued shares (excluding 7.08 million treasury shares) were outstanding, bringing total issued shares to 998.96 million. During the month, 69.26 million ordinary shares were issued, resulting in 1.06 billion issued shares (excluding 7.08 million treasury shares) at the end of February 2026, while total issued shares (including treasury shares) reached approximately 1.07 billion.

The company confirmed that it satisfied the applicable public float requirement of 25%. According to disclosures, there were 800,000 shares repurchased in April 2025 and 4.99 million shares repurchased between October and December 2025 that have not yet been cancelled as of 28 February 2026. A placing of 69.26 million new shares at HKD 12.18 took place on 10 February 2026 based on a placing agreement signed on 3 February 2026.

No other warrants, convertible bonds, or additional share arrangements were reported for the month of February 2026.